
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia Corp has demonstrated a positive outlook based on the substantial increase in estimated sales for its product YUTREPIA, now projected at $1.7B-$2B due to a stronger than expected launch ramp in addressing pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company achieved operating profitability in the first full quarter following YUTREPIA's launch, reflecting its competitive positioning enhanced by the favorable 24-week patient assessment outcomes. Additionally, the promising Phase 3 data for L606 indicates a favorable tolerability profile, bolstering the company's prospects in the biopharmaceutical market.
Bears say
Liquidia Corp faces considerable legal risks that could threaten the exclusivity of YUTREPIA, its primary growth driver, which may impede the company’s top-line revenue potential. Ongoing litigation concerning patent infringement and trade secret misappropriation poses significant downside risks to Liquidia's shares, particularly if unfavorable judgments are rendered that impair YUTREPIA's market presence. Additionally, while the expiration of certain patents may provide a clearer timeline for some legal challenges, the potential for interrupted sales and revenue continuity underscores the company's current valuation discount relative to its growth prospects.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares